Search results
Results From The WOW.Com Content Network
Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the butyrophenone class. It is approved for the treatment of schizophrenia as well as bipolar depression, as either monotherapy or adjunctive therapy (with lithium or valproate). [2]
This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for weight loss, and supplements for heart health.
Ensho plans to initiate Phase 2 clinical development of NSHO-101 as a potential treatment for UC in the first half of 2025. About Ensho Therapeutics, Inc. Ensho Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases. The company ...
This acquisition was followed by the purchase of ZyStor Therapeutics, Inc. (ZyStor), a privately held biotechnology company developing ERTs for the treatment of lysosomal storage disorders and its lead product candidate, ZC-701, a fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for Pompe disease. [13]
Illustrating this trend, in March 2024, Tonix Pharmaceuticals Holding Corp. collaborated with EVERSANA®, a prominent global commercialization services provider, to support the launch strategy and commercial planning for Tonmya™ (TNX-102 SL), a fibromyalgia drug in development for the U.S. market.
LONDON AND PHILADELPHIA, March 07, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, ‘the Company’), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, announces that it has sold Launch Diagnostics Holdings Limited (“Launch Diagnostics”) and its subsidiaries, its UK-based and largest ...
3. Hypoglycemia. There’s an increased risk of hypoglycemia (low blood sugar levels) when you drink alcohol on Ozempic. If you have type 2 diabetes, Ozempic increases your risk of hypoglycemia on ...
On Tuesday, Coya Therapeutics, Inc. (NASDAQ:COYA) released results from the placebo-controlled Phase 2 trial of LD IL-2 in patients with mild to moderate Alzheimer’s Disease. The data was shared ...